New answers tagged

11

A double-blind, randomized, controlled trial was just published today in NEJM: A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. This is a trial where Hydroxychloroquine was given very early, just as Risch demands in the article you quote. The results were negative: After high-risk or moderate-risk exposure to Covid-19, ...


24

There is no perfect study yet, but the best evidence we have says HCQ doesn't work There are well-known rules for judging the quality of evidence in clinical studies. Since discussion this highly charged question seems to frequently consist of selective citation of studies producing the results some advocated of HCQ want to see, it is worth reviewing those ...


7

In the US, more people have died of COVID-19 in hospitals* (ca. 82,000) than in all other locations (ca. 48,000) from February 1 to July 18, 2020. However, as you surmised, this is the case for many conditions. Hospitals were the single most frequent location of death for respiratory diseases in general (2,3 out of 4,9 million in 1999-2018), as well as for ...


-15

(I got some more clarity after posting the question 5 hours ago) 1. Gilead lost $21B in value when Trump mentioned hydroxychloroquine (HCQ). According to Dr. James Todaro, an investor with a medical background, Hours after Trump’s press conference, GILD dropped 8.7%, and then continued to plummet to $69 per share the following week—erasing $21 billion from ...


Top 50 recent answers are included